Paris **NASH** Symposium

French-US Think Tank

July 6 & 7, 2017

Institut Pasteur 28 Rue du Docteur Roux 75015 Paris

Auditorium du CIS Centre d'Information Scientifique

> Organized by Prof. Arun Sanyal & Prof. Lawrence Serfaty

Virginia Commonwealth University School of Medicine, Richmond, Virginia, US

& Hôpital Saint-Antoine, APHP, Inserm, Université Pierre & Marie Curie, Paris, France



With the partnership of









July 6 & 7, 2017

Organized by Prof. Arun Sanyal & Prof. Lawrence Serfaty

INSTITUT PASTEUR, PARIS

Dear Colleagues

We are delighted to welcome you at the third Paris NASH Symposium 2017.

This French US scientific meeting is a « think tank » aimed to raise future issues in the field of NASH by a panel of international experts. This time, the program will do a deep-dive into the cardiovascular issues related to NASH from pathogenesis to management. Building on last year's in depth discussion of the microbiome and bile acids in the genesis of NASH, this year's program will examine the role of the intestine and inflammation and how they link to fibrosis progression in NASH. The innovation session will provide a platform to discuss several next-generation technologies and their applications for NASH. A major focus of the clinical session will be fibrosis, innovations in its assessment including dual-photon microscopy, collagen fragment analysis and kinetic markers as well as a state of the art lecture on the future of anti-fibrotic therapies by Prof. Scott Friedman. The program will provide a comprehensive update of the regulatory landscape with separate sessions on drug development and evidentiary standards in biomarker development.

New abstract-driven programming and working interactive sessions with key opinion leaders and leadership of current EU (IMI) and NIH (USA) efforts in developing non-invasive assessments for NASH will also be provided.

As in previous years, the meeting will be held at the venerable Institut Pasteur in the city center of Paris.

We hope you an enjoyable meeting.

Sincerely

Arun Sanyal & Lawrence Serfaty



July 6 & 7, 2017, Paris **Scientific Program**

French-US Think Tank

	THURSDAY, JULY 6, 2017
08:00 - 08:30 am	CONFERENCE OPENING
08:30 - 08:35 am	Welcome Remarks by Lawrence Serfaty (FR)
08:35 - 08:45 am	Inauguration Address by Stanislas Pol (FR)
08:45 - 10:15 am	SESSION 1 • NASH IN OTHER SETTINGS Chairs: Arun Sanyal (US) and Patrick Marcellin (FR)
08:45 - 09:00 am	NASH in HIV: how big is the problem? Maud Lemoine (UK)
09:00 - 09:15 am	Are the therapeutic targets for NASH in HIV the same as in garden-variety NASH? Richard Sterling (US)
09:15 - 09:30 am	The burden of NASH before and after liver transplantation Rajender Reddy (US)
09:30 - 09:45 am	Is NASH responsible for disease progression after SVR in subjects with HCV? Lawrence Serfaty (FR)
09:45 - 10:15 am	Discussion
10:15 - 10:45 am	COFFEE BREAK AND POSTERS (EXHIBITION AREA)
10:45 - 11:50 am	SESSION 2 • GETTING TO THE HEART OF THE MATTER Chairs: Bruno Vergès (FR) and Ariel Cohen (FR)
10:45 - 11:00 am	Atherogenic risk factors and cardiac outcomes in NASH Raluca Pais (FR)
11:00 - 11:15 am	NASH and the myocardium Mohammad Siddiqui (US)
11:15 - 11:30 am	QTc and NASH-from molecular biology to clinical significance Franck Boccara (FR)
11:30 - 11:50 am	Discussion
11:50 - 12:55 pm	SESSION 3 • CLINICAL HOT TOPICS Chairs: Mohammad Siddiqui (US) and Philippe Mathurin (FR)
11:50 - 12:05 pm	Disease burden report for Europe Homie Razavi (US)
12:05 - 12:20 pm	Prospective assessment of disease evolution in NASH Arun Sanyal (US)
12:20 - 12:35 pm	DILI phenotypes and its assessment in NASH Robert Fontana (US)
12:35 - 12:55 pm	Discussion



01:00 - 02:00 pm LUNCH AND POSTERS

02:00 - 03:30 pm	SESSION 4 • THE ROLE OF THE GUT IN NASH Chairs: Lawrence Serfaty (FR) and Gyongyi Szabo (US)
02:00 - 02:15 pm	The molecular regulation of the intestinal barrier Asma Nusrat (US)
02:15 - 02:30 pm	Endocrine signaling from the gut and its implications for NASH Bart Staels (FR)
02:30 - 02:45 pm	Impact of macronutrient constituents of diet on NASH phenotype and outcomes Jean-Francois Dufour (CH)
02:45 - 03:00 pm	Diet-microbiome interactions and NASH Puneet Puri (US)
03:00 - 03:30 pm	Discussion
03:30 - 04:00 pm	COFFEE BREAK AND POSTERS (EXHIBITION AREA)
04:00 - 05:30 pm	SESSION 5 • INFLAMMATION Chairs: Alexandre Louvet (FR) and Stanislas Pol (FR)
04:00 - 04:15 pm	Gut derived activators of inflammation in NASH Gyongyi Szabo (US)
04:15 - 04:30 pm	Intrahepatic intracellular activators of innate immunity in NASH Wajahat Mehal (US)
04:30 - 04:45 pm	Role of macrophages in disease development and progression Frank Tacke (DE)
04:45 - 05:00 pm	Adipose tissue inflammation in type 2 diabetes and NASH Karine Clement (FR)
05:00 - 05:30 pm	Discussion
05:30 - 06:35 pm	SESSION 6 • TECHNOLOGIC INNOVATIONS IN NASH Chairs: Rohit Loomba (US) and Jean-Pierre Bronowicki (FR)
05:30 - 05:45 pm	Hijacking the microbiome to modify NASH Dean Falb (US)
05:45 - 06:00 pm	Endoscopic treatment of Diabetes and NASH Harith Rajagopalan (US)
06:00 - 06:15 pm	Nanoparticle based anti-fibrotic therapies in NASH Wenbin Ying (US)
06:15 - 06:35 pm	Discussion
06:35 - 06:45 pm	The Copper - NAFLD connection: Role of hepatic copper deficiency Peter Ferenci (AT)
06:45 - 07:00 pm	POSTER AWARDS



July 6 & 7, 2017, Paris Scientific Program

French-US Think Tank

FRIDAY, JULY 7, 2017

08:30 - 09:00 am CONFERENCE OPENING

09:00 - 10:30 am	SESSION 7 • INNOVATIONS IN FIBROSIS ASSESSMENT Chairs: Pierre Bedossa (FR) and Scott Friedman (US)
09:00 - 09:15 am	New algorithms for assessment of fibrosis in NAFLD Jérôme Boursier (FR)
09:15 - 09:30 am	Dual photon microscopy and its potential for assessing fibrosis evolution Arun Sanyal (US)
09:30 - 09:45 am	Potential role of deuterated markers in assessment of fibrosis Rohit Loomba (US)
09:45 - 10:00 am	Assessing fibrosis using antibodies to collagen epitopes Morten Karsdal (DK)
10:00 - 10:30 am	Discussion
10:30 - 11:00 am	COFFEE BREAK (EXHIBITION AREA)

11:00 - 12:05 pm SESSION 8 • SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT

Chairs: Arun Sanyal (US) and Dominique Larrey (FR)

- 11:00 11:15 am Seamless drug development paradigms Claudia Filozof (UK)
- 11:15 11:30 am **Point of Care tests for the diagnosis of NASH in clinical trials, design consideration and potential use** Karine Lacombe (FR)
- 11:30 11:45 am Causality assessment in large data: potential applications for NASH Speaker TBC
- 11:45 12:05 pm **Discussion**

12:05 - 12:30 pm	SESSION 9 • REGULATORY LANDSCAPE Chair: Lawrence Serfaty (FR)
12:05 - 12:20 pm	What is new on the regulatory front?

Veronica Miller (US)

12:20 - 12:30 pm **Discussion**

12:30 - 01:45 pm

NEW WORKING LUNCHES SESSION



NEW	
12:30 - 01:45 pm	WORKING LUNCHES SESSION
GROUP 1:	Transatlantic Biomarker Development Julia Brosnan (US) and Sudha Shankar (US)
GROUP 2:	NASH cohorts for clinical trials around the world Arun Sanyal (US) and Vlad Ratziu (FR)
GROUP 3:	The place of bariatric surgery in NASH: can we extend the indications? Philippe Mathurin (FR) and Nicolas Goossens (CH)
01:45 - 02:15 pm	SESSION 10 • STATE OF THE ART LECTURE Chair: Arun Sanyal (US)
	Past, present and future of therapeutics for liver fibrosis Scott Friedman (US)
02:15 - 03:45 pm	SESSION 11 • INDUSTRY FORUM Chairs: Lawrence Serfaty (FR) and Arun Sanyal (US)
02:15 - 03:15 pm	Sponsor session
03:15 - 03:45 pm	Panel Discussion
03:45 pm	Closing Remarks by Arun Sanyal (US)

Paris Paris Symposium

www.parts-nash-sympostum.org



July 6 & 7, 2017, Paris

INSTITUT PASTEUR

28 Rue du Docteur Roux 75015 PARIS • FRANCE

Congress Secretariat

QUADRATURE SANTÉ 43 rue des Tilleuls 92100 Boulogne-Billancourt

Contacts:

Claire NOBILET-SEGUIN claire.nobilet-seguin@quadrature.fr

Lony CASTANS-BOITEAU lony.castans-boiteau@quadrature.fr

Phone: +33 1 41 10 46 67 +33 6 71 44 77 94

<u>Registration fee*</u>

Pr, Dr, MD, Ph.D: 300 € TTC SFD member: 150 € TTC Student/Fellow: 75 € TTC

Dead-line registration: June 6, 2017

*Registration fee includes

Access to all congress sessions - plenary & working lunches - and exhibition area, delegate bag, coffee breaks and lunches during the congress

The Paris NASH Symposium is supported by









U NOVARTIS



